Combining ERK inhibitors with BRAF inhibitors in several tumor types (195, 196) and BRAFV600E mutated colon cancer (109) exhibits a similar synergism, with SHP2 inhibition as promising additional partner. This evidence concerns the gene BRAF and malignant colon neoplasm.